NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms NEXT
- 07 Jun 2017 Biomarkers information updated
- 09 Mar 2017 Status changed from completed to discontinued.
- 01 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.